MX2022013425A - Composicion para reducir los trigliceridos hepaticos y/o mejorar el metabolismo de la glucosa. - Google Patents

Composicion para reducir los trigliceridos hepaticos y/o mejorar el metabolismo de la glucosa.

Info

Publication number
MX2022013425A
MX2022013425A MX2022013425A MX2022013425A MX2022013425A MX 2022013425 A MX2022013425 A MX 2022013425A MX 2022013425 A MX2022013425 A MX 2022013425A MX 2022013425 A MX2022013425 A MX 2022013425A MX 2022013425 A MX2022013425 A MX 2022013425A
Authority
MX
Mexico
Prior art keywords
composition
glucose metabolism
improving glucose
reducing hepatic
hepatic triglycerides
Prior art date
Application number
MX2022013425A
Other languages
English (en)
Inventor
Hana Koutnikova
André Marette
Original Assignee
Gervais Danone Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gervais Danone Sa filed Critical Gervais Danone Sa
Publication of MX2022013425A publication Critical patent/MX2022013425A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dairy Products (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a una composición que comprende metabolitos de aminoácidos de cadena ramificada para su uso en la reducción de los triglicéridos hepáticos y/o la mejora del metabolismo de la glucosa en un individuo.
MX2022013425A 2020-04-27 2021-04-27 Composicion para reducir los trigliceridos hepaticos y/o mejorar el metabolismo de la glucosa. MX2022013425A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063015872P 2020-04-27 2020-04-27
PCT/IB2021/000311 WO2021220059A1 (en) 2020-04-27 2021-04-27 Composition for reducing hepatic triglycerides and/or improving glucose metabolism

Publications (1)

Publication Number Publication Date
MX2022013425A true MX2022013425A (es) 2023-01-16

Family

ID=76269763

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013425A MX2022013425A (es) 2020-04-27 2021-04-27 Composicion para reducir los trigliceridos hepaticos y/o mejorar el metabolismo de la glucosa.

Country Status (6)

Country Link
US (1) US20230165818A1 (es)
EP (1) EP4142708A1 (es)
BR (1) BR112022021309A2 (es)
CA (1) CA3176496A1 (es)
MX (1) MX2022013425A (es)
WO (1) WO2021220059A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2868017A1 (en) * 2012-03-19 2013-09-26 Abbott Laboratories Beta-hydroxy-beta-methylbutyric acid for improving glucose tolerance
BR112015014693A2 (pt) * 2012-12-20 2017-10-10 Gervais Danone Sa uso de bifidobacterium animalis para o tratamento ou a prevenção de ganho de peso corpóreo e resistência à insulina
CA2923705C (en) * 2013-10-09 2024-05-14 Nestec S.A. Compositions comprising citrulline and leucine and their use in the treatment of diabetes and metabolic syndrome

Also Published As

Publication number Publication date
WO2021220059A1 (en) 2021-11-04
BR112022021309A2 (pt) 2022-12-06
US20230165818A1 (en) 2023-06-01
CA3176496A1 (en) 2021-11-04
EP4142708A1 (en) 2023-03-08

Similar Documents

Publication Publication Date Title
NZ717728A (en) Stable formulations of a hyaluronan-degrading enzyme
MX2019011219A (es) Administracion rapida y controlada de composiciones con efectos sequito restaurados.
BRPI0617294B8 (pt) composição farmacêutica em gel hidroalcóolico e uso de testosterona
DE602006015042D1 (de) Nahrungsergänzungsmittel für hiv-patienten
AU2008313418A8 (en) Composition for regulating lipid metabolism
WO2007058538A3 (en) Composition with docosapentaenoic acid
MX2010008287A (es) Composicion mejorada, aclaradora de la piel.
BR112012026379A2 (pt) métodos para gerar proteína endogenamente marcada
TW200716191A (en) Improved cosmetic composition
PL2252284T3 (pl) Kompozycja farmaceutyczna entakaponu, lewodopy i karbidopy o poprawionej dostępności biologicznej
TW200741277A (en) Holding device and exposure apparatus using the same
MX2010004389A (es) Formulaciones de vancomicina liposomales.
MX2009008511A (es) Reduccion de efectos secundarios de tramadol.
MX337195B (es) Composiciones y metodos para tratar condiciones dermatologicas.
AR077384A1 (es) Una formulacion farmaceutica inyectable de melfalano.
UA100394C2 (en) Lipoic acid pellet composition
TW200726460A (en) Anti-fatigue composition
BR112012016054A2 (pt) Composições nutricionais compreendendo flocos de fruta incluindo ácido docosa-hexaenoico
MX2022013425A (es) Composicion para reducir los trigliceridos hepaticos y/o mejorar el metabolismo de la glucosa.
MX2014001767A (es) Metodos para reducir sintomas o condiciones causados por estres.
WO2010028336A3 (en) Fatty acid c16:1n7-palmitoleate a lipokine and biomarker for metabolic status
BRPI0519812A2 (pt) método para a obtenção de células de algas castanhas liofilizadas
AR058621A1 (es) Metodods para reducir la proteina c reactiva
ATE533482T1 (de) Verfahren zur gewichtsreduktion
GEP20084378B (en) Composition with hepatoproective and metabolism normalizing activity